{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cbv1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2022-09-06T17:00:00.000Z","role":"Approver"},{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2022-09-06T17:02:24.983Z","role":"Publisher"}],"evidence":[{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:d7bc5ccf-8547-4186-a3ac-60cfdc696b59_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:d7bc5ccf-8547-4186-a3ac-60cfdc696b59","type":"Proband","allele":{"id":"cggv:4c568fb4-713a-47e7-abdb-43bf29d6a952","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.185T>A (p.Val62Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366633263"}},"phenotypes":["obo:HP_0000657","obo:HP_0001251"],"sex":"UnknownEthnicity","variant":{"id":"cggv:231ff3c1-bec7-4350-b14a-017febeea48e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4c568fb4-713a-47e7-abdb-43bf29d6a952"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/33163565","type":"dc:BibliographicResource","dc:abstract":"Cerebellar atrophy is a nonspecific imaging finding observed in a number of neurological disorders. Genetic ataxias associated with cerebellar atrophy are a heterogeneous group of conditions, rendering the approach to diagnosis challenging.","dc:creator":"Gauquelin L","dc:date":"2020","dc:title":"Channelopathies Are a Frequent Cause of Genetic Ataxias Associated with Cerebellar Atrophy."}},"rdfs:label":"619"},{"id":"cggv:231ff3c1-bec7-4350-b14a-017febeea48e","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:231ff3c1-bec7-4350-b14a-017febeea48e_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:4b911110-4ea4-4720-a1e6-d41cea336891_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:4b911110-4ea4-4720-a1e6-d41cea336891","type":"Proband","allele":{"id":"cggv:12c34848-a32b-4880-a034-356d05cf3486","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.925_930del (p.Pro309_Gln310del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051212"}},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001251","obo:HP_0001260","obo:HP_0007360","obo:HP_0001270","obo:HP_0001252","obo:HP_0001249"],"sex":"Male","variant":{"id":"cggv:af417681-16fc-42e3-84ba-a708a1012af2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12c34848-a32b-4880-a034-356d05cf3486"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29997391","type":"dc:BibliographicResource","dc:abstract":"To investigate the genetic basis of congenital ataxias (CAs), a unique group of cerebellar ataxias with a nonprogressive course, in 20 patients from consanguineous families, and to identify new CA genes.","dc:creator":"Valence S","dc:date":"2019","dc:title":"Exome sequencing in congenital ataxia identifies two new candidate genes and highlights a pathophysiological link between some congenital ataxias and early infantile epileptic encephalopathies."}},"rdfs:label":"P8"},{"id":"cggv:af417681-16fc-42e3-84ba-a708a1012af2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:af417681-16fc-42e3-84ba-a708a1012af2_variant_evidence_item"}],"strengthScore":0.5,"dc:description":"inframe homozygous deletion identified in multiple probands with disease. See P7 and P9"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:c0b19fcc-62f2-4838-aab0-4ffd435348bc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:c0b19fcc-62f2-4838-aab0-4ffd435348bc","type":"Proband","allele":{"id":"cggv:12c34848-a32b-4880-a034-356d05cf3486"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000733","obo:HP_0001249","obo:HP_0007360","obo:HP_0001319","obo:HP_0001257","obo:HP_0001270","obo:HP_0001251","obo:HP_0001310","obo:HP_0001260"],"sex":"Female","variant":{"id":"cggv:5d0d6291-0bdd-4e52-846b-51fe63550278_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12c34848-a32b-4880-a034-356d05cf3486"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29997391"},"rdfs:label":"P7"},{"id":"cggv:5d0d6291-0bdd-4e52-846b-51fe63550278","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:5d0d6291-0bdd-4e52-846b-51fe63550278_variant_evidence_item"}],"strengthScore":0.5,"dc:description":"In-frame deletion, homozygous in multiple individuals with disease- see proband P8 and P9"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:eea62c9d-a0b8-4232-8a81-e863510b4db5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:eea62c9d-a0b8-4232-8a81-e863510b4db5","type":"Proband","allele":[{"id":"cggv:256b088e-874a-4497-8204-5d37446c851c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.491C>T (p.Ala164Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4128182"}},{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.638dup (p.Val214fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA129742"}}],"sex":"UnknownEthnicity","variant":[{"id":"cggv:50f82ab8-9f23-49d8-91cc-e2c06337d737_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:256b088e-874a-4497-8204-5d37446c851c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29997391"},{"id":"cggv:e3973343-7c36-433e-9bcb-f619aa6f4d0c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29997391"}],"rdfs:label":"UNK-2"},{"id":"cggv:e3973343-7c36-433e-9bcb-f619aa6f4d0c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:e3973343-7c36-433e-9bcb-f619aa6f4d0c_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:50f82ab8-9f23-49d8-91cc-e2c06337d737","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:50f82ab8-9f23-49d8-91cc-e2c06337d737_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:e1fac5c9-6cd2-41fd-bf75-0fc1d2681e9e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:e1fac5c9-6cd2-41fd-bf75-0fc1d2681e9e","type":"Proband","allele":{"id":"cggv:4c568fb4-713a-47e7-abdb-43bf29d6a952"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001272","obo:HP_0012758","obo:HP_0000657"],"previousTesting":true,"previousTestingDescription":"Extensive metabolic and other laboratory investigations, including microarray and serum alpha-fetoprotein\n(AFP) were normal, as were EMG and nerve conduction studies.","sex":"Male","variant":{"id":"cggv:fdbd5875-4b6f-48f2-9f96-1a39cf17b288_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4c568fb4-713a-47e7-abdb-43bf29d6a952"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/31742228","type":"dc:BibliographicResource","dc:abstract":"To investigate the pathogenicity of a novel homozygous ","dc:creator":"Mahjoub A","dc:date":"2019","dc:title":"Homozygous pathogenic variant in "}},"rdfs:label":"Mahjoub 1"},{"id":"cggv:fdbd5875-4b6f-48f2-9f96-1a39cf17b288","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:fdbd5875-4b6f-48f2-9f96-1a39cf17b288_variant_evidence_item"},{"id":"cggv:fdbd5875-4b6f-48f2-9f96-1a39cf17b288_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Markedly reduced the level of BRAT1 protein in patient derived cell lines from both affected siblings (figure 2, A and B). This reduction was not due to decreased levels of BRAT1 mRNA, which were similar in the patients’ and parental cells (figure 2C), suggesting instead that itmight reflect instabilityof the mutant BRAT1 protein"}],"strengthScore":0.1,"dc:description":"missense variant, functional evidence present but not specifically tied to variant."}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:da7f7b6d-8c40-49c9-ac26-aacab3230147_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:da7f7b6d-8c40-49c9-ac26-aacab3230147","type":"Proband","allele":[{"id":"cggv:cc27b38e-768c-4e70-b0c4-73078fec2720","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.968C>T (p.Pro323Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366630304"}},{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"}],"sex":"UnknownEthnicity","variant":[{"id":"cggv:435450e6-cfeb-4e49-bd17-9e0411e5ed7a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:cc27b38e-768c-4e70-b0c4-73078fec2720"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29997391"},{"id":"cggv:31ba309c-ad9f-498a-94c2-cc5dd7b0258e_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29997391"}],"rdfs:label":"UNK-1"},{"id":"cggv:435450e6-cfeb-4e49-bd17-9e0411e5ed7a","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:435450e6-cfeb-4e49-bd17-9e0411e5ed7a_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:31ba309c-ad9f-498a-94c2-cc5dd7b0258e","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:31ba309c-ad9f-498a-94c2-cc5dd7b0258e_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0a21816e-5afb-45db-af1d-6c64cec98515_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0a21816e-5afb-45db-af1d-6c64cec98515","type":"Proband","allele":{"id":"cggv:12c34848-a32b-4880-a034-356d05cf3486"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001270","obo:HP_0001252","obo:HP_0001251","obo:HP_0007360","obo:HP_0001249","obo:HP_0001260"],"sex":"Male","variant":{"id":"cggv:a6e24cfb-2033-4ad3-9e09-b38e5da9f3e4_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:12c34848-a32b-4880-a034-356d05cf3486"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/29997391"},"rdfs:label":"P9"},{"id":"cggv:a6e24cfb-2033-4ad3-9e09-b38e5da9f3e4","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:a6e24cfb-2033-4ad3-9e09-b38e5da9f3e4_variant_evidence_item"}],"strengthScore":0.5,"dc:description":"Inframe homozygous deletion identified in multiple probands with disease. See P7 and P8"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:fb2c51f1-914a-4fda-b60e-e6c295554100_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:fb2c51f1-914a-4fda-b60e-e6c295554100","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":[{"id":"cggv:8b91c397-e391-4984-8203-2109415339d5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.294dup (p.Leu99fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4128245"}},{"id":"cggv:7aa70359-e541-40f7-84b5-47089290a4ee","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.1925C>A (p.Ala642Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4127515"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001999","obo:HP_0001276","obo:HP_0000252"],"previousTesting":true,"previousTestingDescription":"The work-up included normal testing for inborn errors of metabolism, SNP chromosome microarray, and MeCP2 analyses. A muscle biopsy showed increased activity of all respiratory chain\ncomplexes and no specific deficiencies. EEGs displayed mainly leftsided temporo-occipital epileptiform discharges and absence of a\nposterior dominant rhythm. Brain MRI showed decreased myelination and thin corpus callosum at 3months, and right temporal lobe\nencephalomalacia and cerebellar and vermis hypoplasia at 3 years.","sex":"Female","variant":[{"id":"cggv:aa9ce886-f00b-4164-9df9-59e0af723097_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:8b91c397-e391-4984-8203-2109415339d5"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26494257","type":"dc:BibliographicResource","dc:abstract":"We present a patient with neonatal onset of hypertonia and seizures identified through whole exome sequencing to have compound heterozygous variants, c.294dupA (p.Leu99fs) and c.1925C>A (p.Ala642Glu), in the BRCA1-associated protein required for ATM activation-1 (BRAT1) gene. Variants in BRAT1 have been identified to cause lethal neonatal rigidity and multifocal seizure syndrome (OMIM# 614498), which consistently manifests a severe neurological phenotype that includes neonatal presentation of rigidity and hypertonia, microcephaly and arrested head growth, intractable seizures, absence of developmental progress, apneic episodes, and death usually by 6 months of age. Our patient initially had a similarly severe neurological picture but remains alive at 6 years of age, expanding the phenotype to include longer term survival and providing further insights into genotype-phenotype correlations and the natural history of this disease.","dc:creator":"Mundy SA","dc:date":"2016","dc:title":"BRAT1-related disease--identification of a patient without early lethality."}},{"id":"cggv:82482659-bdc3-4822-8d56-8be1ca2efc79_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:7aa70359-e541-40f7-84b5-47089290a4ee"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26494257"}],"rdfs:label":"Mundy 1"},{"id":"cggv:aa9ce886-f00b-4164-9df9-59e0af723097","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:aa9ce886-f00b-4164-9df9-59e0af723097_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:82482659-bdc3-4822-8d56-8be1ca2efc79","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:82482659-bdc3-4822-8d56-8be1ca2efc79_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:ce7dfbc7-c2b7-4709-92df-3901c82aef03_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:ce7dfbc7-c2b7-4709-92df-3901c82aef03","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":[{"id":"cggv:8b91c397-e391-4984-8203-2109415339d5"},{"id":"cggv:c88940f1-8e86-4296-bf32-87517e28c3ae","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.1825C>T (p.Arg609Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10588424"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0012758","obo:HP_0001276","obo:HP_0000505","obo:HP_0001250","obo:HP_0001347","obo:HP_0000252"],"previousTesting":true,"previousTestingDescription":"7-dehydroxycholesterol, isoelectric\nfocusing of transferrin, acylcarnitines, urine sulfatides, urine mucopolysaccharide\nscreen, cerebral spinal fluid neurotransmitter analysis,48-hour Holter monitoring, and echocardiography, all of which were\nnormal. ","sex":"Female","variant":[{"id":"cggv:c4cbcf8c-d1a9-479f-b3c0-e5760712f198_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:c88940f1-8e86-4296-bf32-87517e28c3ae"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26483087","type":"dc:BibliographicResource","dc:abstract":"Lethal neonatal rigidity and multifocal seizure syndrome is a newly recognized genetic disorder associated with early onset of rigidity, multifocal epilepsy, developmental arrest, and early death. It is an autosomal recessive condition resulting from a mutation in the BRAT1 (BRCA1 [breast cancer-1]-associated ataxia telangiectasia mutated activator 1) gene. There are few cases in the literature, and all patients have died before age 2 years, most within the first 6 months of life. The objective of this report is to expand the phenotypic spectrum of BRAT1 disorders and propose new nomenclature for this condition.","dc:creator":"Hanes I","dc:date":"2015","dc:title":"Lethal Neonatal Rigidity and Multifocal Seizure Syndrome--A Misnamed Disorder?"}},{"id":"cggv:3baa0dfa-dd45-4f2f-9967-bc7e865f4ce7_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:8b91c397-e391-4984-8203-2109415339d5"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26483087"}],"rdfs:label":"Hanes 1"},{"id":"cggv:3baa0dfa-dd45-4f2f-9967-bc7e865f4ce7","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:3baa0dfa-dd45-4f2f-9967-bc7e865f4ce7_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:c4cbcf8c-d1a9-479f-b3c0-e5760712f198","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:c4cbcf8c-d1a9-479f-b3c0-e5760712f198_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:85a4d81c-00b5-4869-9753-00adf70921d8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:85a4d81c-00b5-4869-9753-00adf70921d8","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":4,"allele":[{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"},{"id":"cggv:e021fb64-5d1f-4b5b-a087-d2ddfa18cc1c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.1564G>A (p.Glu522Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/840355"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000252","obo:HP_0001252","obo:HP_0012758"],"previousTesting":true,"previousTestingDescription":"The results of routine laboratory screening, including thyroid function, and neurometabolic\ntests were within normal range. Lactic and pyruvic acid were normal in serum and cerebrospinal fluid. Mitochondrial respiratory chain enzymatic activities on muscle tissue were normal at the age of 3 years old. Sleep and sleep-deprived video-EEG tests performed at the ages of 1, 2 and 4 years old, displayed normal results (Fig. 1). The eye and ear examinations yielded normal results. In addition, both visual and auditory evoked potentials were normal at the age of 3 years old.","sex":"Male","variant":[{"id":"cggv:75733959-c390-464d-b5c1-f5eb38fa89eb_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:e021fb64-5d1f-4b5b-a087-d2ddfa18cc1c"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26947546","type":"dc:BibliographicResource","dc:abstract":"We describe a 4-year-old male child born to non-consanguineous Spanish parents with progressive encephalopathy (PE), microcephaly, and hypertonia. Whole exome sequencing revealed compound heterozygous BRAT1 mutations [c.1564G > A (p.Glu522Lys) and c.638dup (p.Val214Glyfs*189)]. Homozygous and compound heterozygous BRAT1 mutations have been described in patients with lethal neonatal rigidity and multifocal seizure syndrome (MIM# 614498). The seven previously described patients suffered from uncontrolled seizures, and all of those patients died in their first months of life. BRAT1 acts as a regulator of cellular proliferation and migration and is required for mitochondrial function. The loss of these functions may explain the cerebral atrophy observed in this case of PE. This case highlights the extraordinary potential of next generation technologies for the diagnosis of rare genetic diseases, including PE. Making a prompt diagnosis of PE is important for genetic counseling and disease management.","dc:creator":"Fernández-Jaén A","dc:date":"2016","dc:title":"Mutations in BRAT1 cause autosomal recessive progressive encephalopathy: Report of a Spanish patient."}},{"id":"cggv:66548406-652a-46d8-9976-470d1725e2aa_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/26947546"}],"rdfs:label":"Fernández 1"},{"id":"cggv:75733959-c390-464d-b5c1-f5eb38fa89eb","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:75733959-c390-464d-b5c1-f5eb38fa89eb_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:66548406-652a-46d8-9976-470d1725e2aa","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:66548406-652a-46d8-9976-470d1725e2aa_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:45eeb6ca-0709-419e-8591-e8c9a785f202_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:45eeb6ca-0709-419e-8591-e8c9a785f202","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":4,"allele":[{"id":"cggv:0b49ba13-18e7-4ebc-8379-188e3d5b9b18","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.171del (p.Glu57fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/559429"}},{"id":"cggv:3a3f03b2-1724-4c94-9238-3613e487545b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.419T>C (p.Leu140Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366632769"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0000252","obo:HP_0002059","obo:HP_0001276","obo:HP_0002015","obo:HP_0100704","obo:HP_0032792"],"sex":"Male","variant":[{"id":"cggv:3b9a3065-1eeb-4a9f-b94e-c62c2a0b536b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:0b49ba13-18e7-4ebc-8379-188e3d5b9b18"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27282546","type":"dc:BibliographicResource","dc:abstract":"Mutations in BRAT1, encoding BRCA1-associated ATM activator 1, are associated with a severe phenotype known as rigidity and multifocal seizure syndrome, lethal neonatal (RMFSL; OMIM # 614498), characterized by intractable seizures, hypertonia, autonomic instability, and early death. We expand the phenotypic spectrum of BRAT1 related disorders by reporting on four individuals with various BRAT1 mutations resulting in clinical severity that is either mild or moderate compared to the severe phenotype seen in RMFSL. Representing mild severity are three individuals (Patients 1-3), who are girls (including two sisters, Patients 1-2) between 4 and 10 years old, with subtle dysmorphisms, intellectual disability, ataxia or dyspraxia, and cerebellar atrophy on brain MRI; additionally, Patient 3 has well-controlled epilepsy and microcephaly. Representing moderate severity is a 15-month-old boy (Patient 4) with severe global developmental delay, refractory epilepsy, microcephaly, spasticity, hyperkinetic movements, dysautonomia, and chronic lung disease. In contrast to RMFSL, his seizure onset occurred later at 4 months of age, and he is still alive. All four of the individuals have compound heterozygous BRAT1 mutations discovered via whole exome sequencing: c.638dupA (p.Val214Glyfs*189); c.803+1G>C (splice site mutation) in Patients 1-2; c.638dupA (p.Val214Glyfs*189); c.419T>C (p.Leu140Pro) in Patient 3; and c.171delG (p.Glu57Aspfs*7); c.419T>C (p.Leu140Pro) in Patient 4. Only the c.638dupA (p.Val214Glyfs*189) mutation has been previously reported in association with RMFSL. These patients illustrate that, compared with RMFSL, BRAT1 mutations can result in both moderately severe presentations evident by later-onset epilepsy and survival past infancy, as well as milder presentations that include intellectual disability, ataxia/dyspraxia, and cerebellar atrophy. © 2016 Wiley Periodicals, Inc.","dc:creator":"Srivastava S","dc:date":"2016","dc:title":"BRAT1 mutations present with a spectrum of clinical severity."}},{"id":"cggv:7557c7f8-d295-46f4-b71b-a7fd4fd059d5_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:3a3f03b2-1724-4c94-9238-3613e487545b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27282546"}],"rdfs:label":"Patient 4"},{"id":"cggv:7557c7f8-d295-46f4-b71b-a7fd4fd059d5","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:7557c7f8-d295-46f4-b71b-a7fd4fd059d5_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:3b9a3065-1eeb-4a9f-b94e-c62c2a0b536b","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:3b9a3065-1eeb-4a9f-b94e-c62c2a0b536b_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:34dce684-7a60-488c-8fbe-33db0a904efb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:34dce684-7a60-488c-8fbe-33db0a904efb","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":8,"allele":[{"id":"cggv:357ba280-beae-4929-ac26-de755ab3c25e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_152743.4(BRAT1):c.803+1G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA358005"}},{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001272","obo:HP_0000639","obo:HP_0001252","obo:HP_0001260","obo:HP_0000486","obo:HP_0001249","obo:HP_0001310","obo:HP_0000252","obo:HP_0001332","obo:HP_0000733","obo:HP_0001251"],"sex":"UnknownEthnicity","variant":[{"id":"cggv:744485ce-09ef-4aca-8c68-62976d16913c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:357ba280-beae-4929-ac26-de755ab3c25e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25131622","type":"dc:BibliographicResource","dc:abstract":"Whole exome sequencing (WES) represents a significant breakthrough in clinical genetics as a powerful tool for etiological discovery in neurodevelopmental disorders. To better characterize the genetic landscape of neurodevelopmental disorders, we analyzed patients in our pediatric neurogenetics clinic who underwent WES.","dc:creator":"Srivastava S","dc:date":"2014","dc:title":"Clinical whole exome sequencing in child neurology practice."}},{"id":"cggv:f040d437-727f-4da3-827a-311bf0b09d35_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25131622"}],"rdfs:label":"29"},{"id":"cggv:f040d437-727f-4da3-827a-311bf0b09d35","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:f040d437-727f-4da3-827a-311bf0b09d35_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:744485ce-09ef-4aca-8c68-62976d16913c","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:744485ce-09ef-4aca-8c68-62976d16913c_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:8cd6ce66-c7c2-430e-9886-b9e25d2d1a30_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8cd6ce66-c7c2-430e-9886-b9e25d2d1a30","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":5,"allele":[{"id":"cggv:3a3f03b2-1724-4c94-9238-3613e487545b"},{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002194","obo:HP_0040019","obo:HP_0000252","obo:HP_0000565"],"sex":"Female","variant":[{"id":"cggv:050980a7-e5fa-4d98-924f-c54c74318846_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:b20009e2-b38f-4154-8886-14654f6ecc1e"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27282546"},{"id":"cggv:737b4205-e4b3-423a-b307-063361e30220_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:3a3f03b2-1724-4c94-9238-3613e487545b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27282546"}],"rdfs:label":"Patient 3 "},{"id":"cggv:050980a7-e5fa-4d98-924f-c54c74318846","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:050980a7-e5fa-4d98-924f-c54c74318846_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:737b4205-e4b3-423a-b307-063361e30220","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:737b4205-e4b3-423a-b307-063361e30220_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:0933c569-3c14-4951-8105-3b5615c0862e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0d841d96-f7b2-4a9a-bbd1-e5eef5b3746d","type":"Finding","demonstrates":{"id":"cg:GeneExpressionB"},"dc:description":"\"Markedly reduced level of BRAT1 protein in patient derived cell lines. Indeed, although we could not restore normal levels of BRAT1 protein in the patient cells by incubation with the proteasome inhibitor MG132(figure 2B), incubation with cycloheximide to prevent nascent protein synthesis revealed that the half-life of the mutant protein was much shorter than the parental BRAT1\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31742228","rdfs:label":"Western Blot of BRAT1 in Patient Derived Cell Lines"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:09751024-9d23-4314-9d12-453cf727b6dc","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:dc45233d-eb86-4ea8-a9ee-5e6350f3a1a0","type":"FunctionalAlteration","dc:description":"Mutant BRAT1 does not localize and forms puncate aggregations in cytoplasm. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/22279524","type":"dc:BibliographicResource","dc:abstract":"The Clinic for Special Children (CSC) has integrated biochemical and molecular methods into a rural pediatric practice serving Old Order Amish and Mennonite (Plain) children. Among the Plain people, we have used single nucleotide polymorphism (SNP) microarrays to genetically map recessive disorders to large autozygous haplotype blocks (mean = 4.4 Mb) that contain many genes (mean = 79). For some, uninformative mapping or large gene lists preclude disease-gene identification by Sanger sequencing. Seven such conditions were selected for exome sequencing at the Broad Institute; all had been previously mapped at the CSC using low density SNP microarrays coupled with autozygosity and linkage analyses. Using between 1 and 5 patient samples per disorder, we identified sequence variants in the known disease-causing genes SLC6A3 and FLVCR1, and present evidence to strongly support the pathogenicity of variants identified in TUBGCP6, BRAT1, SNIP1, CRADD, and HARS. Our results reveal the power of coupling new genotyping technologies to population-specific genetic knowledge and robust clinical data.","dc:creator":"Puffenberger EG","dc:date":"2012","dc:title":"Genetic mapping and exome sequencing identify variants associated with five novel diseases."},"rdfs:label":"Heterologous overexpression of N-terminal FLAG-tagged human "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1}],"evidenceStrength":"Definitive","sequence":4973,"specifiedBy":"GeneValidityCriteria8","strengthScore":13,"subject":{"id":"cggv:b69d831d-35f1-41c2-bc88-1011e4161f34","type":"GeneValidityProposition","disease":"obo:MONDO_0020841","gene":"hgnc:21701","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"Pathogenic variants in the BRAT1 gene have been reported in the literature in several individuals with a broad spectrum of disease with features including epilepsy, developmental delay, hypertonia, microcephaly, spasticity and dysmorphic features. One form of this phenotype associated with BRAT1 has been reported in the literature as neurodevelopmental disorder with cerebellar atrophy and with or without seizures. Another form associated with more severe phenotypes (BRAT1/Neonatal-onset encephalopathy with rigidity and seizures) has been assessed separately. Compared to an earlier onset more severe presentation usually within the first days of life (documented in the literature as rigidity and multifocal seizure syndrome, lethal neonatal- RMFSL), for this phenotype, onset of symptoms is variable, usually around infancy and more attenuated. Clinical presentation is also variable with most individuals reported with developmental delay, microcephaly, hypertonia or hypotonia; of note, seizures have been reported in some but not all individuals with features of disease. \n\nLoss of function variants have been commonly reported in association with disease, however missense and inframe deletions also been reported in the literature (PMIDs: 26483087, 26494257, 31742228, 25131622, 29997391, 27282546). Supporting experimental data has demonstrated that variants in this gene result in the inability for the protein to localize to the nucleus and may affect the stability of the protein (PMIDs: 22279524, 31742228).  \n\nAt the time of this review, no difference in variant type has been noted between the phenotypes of this gene. In addition, the same variant has been identified in both the severe and attenuated forms of this disease.  In all instances the identified variants were either homozygous or compound heterozygous supporting an autosomal recessive inheritance pattern. BRAT1 is definitively associated with neurodevelopmental disorder with cerebellar atrophy and with or without seizures. This has been demonstrated in the clinical and research settings and this evidence has been maintained over time. This classification was approved by the ClinGen Epilepsy Gene Curation Expert Panel on 4/19/22 (SOP version 8). \n","dc:isVersionOf":{"id":"cggv:93a7b6f1-75e5-4f97-be9d-62fb5770b8cb"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}